Coronavirus: Medical Treatments

Department of Health and Social Care written question – answered on 23rd June 2022.

Alert me about debates like this

Photo of Stephen Hammond Stephen Hammond Conservative, Wimbledon

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the role of covid-19 antivirals in reducing pressures on the NHS.

Photo of Maggie Throup Maggie Throup The Parliamentary Under-Secretary for Health and Social Care

No specific assessment has been made. However, clinical trial results indicate that the dual oral antiviral nirmatrelvir/ritonavir resulted in a relative risk reduction of hospitalisation or death by 88% within five days of symptom onset, compared to placebo in non-hospitalised, high-risk adults with COVID-19. Further results show that the oral antiviral molnupiravir administered within five days of symptom onset to high-risk, non-hospitalised patients resulted in a relative risk reduction of 30% in the composite primary outcome of hospitalisation or death at day 29.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.